What is the recommended treatment for severe mitral regurgitation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Treatment of Severe Mitral Regurgitation

The treatment of severe mitral regurgitation depends critically on whether it is primary (degenerative valve disease) or secondary (functional, due to ventricular or atrial dysfunction), with surgical mitral valve repair being the gold standard for primary MR and optimized medical therapy being the mandatory first step for secondary MR. 1, 2

Primary Mitral Regurgitation

Symptomatic Patients

  • Surgery is indicated for all symptomatic patients with severe primary MR, regardless of left ventricular function 1, 2
  • Mitral valve repair is strongly preferred over replacement when feasible 1, 2
  • The procedure should be performed at experienced heart valve centers with high surgical volumes 1

Asymptomatic Patients

Surgery is indicated when any of the following are present:

  • LVEF ≤60% and/or LV end-systolic diameter (LVESD) ≥40 mm 2, 3
  • New-onset atrial fibrillation 2
  • Pulmonary artery systolic pressure >50 mmHg 2

Surgery may be considered in asymptomatic patients with LVEF >60% and LVESD <40 mm when:

  • A durable repair is highly likely at an experienced center 2
  • Progressive LV dilatation or declining function on serial imaging 2

Transcatheter Edge-to-Edge Repair (TEER) for Primary MR

  • TEER may be considered only in symptomatic patients at high or prohibitive surgical risk with favorable valve anatomy 1, 2, 3
  • This is not a first-line option for primary MR—surgery remains superior for durability and outcomes 4

Secondary Mitral Regurgitation

Medical Therapy First

Optimal guideline-directed medical therapy (GDMT) for heart failure is mandatory before considering any valve intervention 1

  • This includes ACE inhibitors/ARBs, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors
  • Cardiac resynchronization therapy (CRT) if indicated 1, 5
  • Reassess MR severity after GDMT optimization—it may improve significantly 1

Surgical Intervention

Surgery is indicated in the following scenarios:

  • Patients undergoing CABG with LVEF >30% (Class I recommendation) 1
  • Patients who remain symptomatic despite optimal GDMT (including CRT), have LVEF >30%, and are at low surgical risk 1

Important caveat: There is no conclusive evidence for survival benefit from isolated mitral valve surgery in secondary MR 1

Transcatheter Edge-to-Edge Repair (TEER) for Secondary MR

TEER should be considered in carefully selected patients who meet ALL of the following criteria:

  • Severe symptomatic MR despite maximally tolerated GDMT (including CRT if indicated) 5
  • LVEF 20-50% 5
  • LV end-systolic diameter <70 mm 5
  • Appropriate valve anatomy for the procedure 1, 2
  • High surgical risk 1, 2

Critical distinction based on COAPT trial criteria: Patients should have proportionate or disproportionate MR relative to LV size (higher EROA relative to smaller ventricles), not just dilated ventricles with mild functional MR 5

Defining Severe Secondary MR

Lower thresholds apply compared to primary MR:

  • EROA ≥20 mm² (vs. ≥40 mm² for primary) 1
  • Regurgitant volume ≥30 mL (vs. ≥60 mL for primary) 1

Common Pitfalls to Avoid

  1. Do not proceed with TEER for secondary MR without first optimizing medical therapy—approximately one-third to one-half of patients still died or were hospitalized at 1 year even after TEER in trials 5

  2. Avoid intervention in secondary MR with LVEF <20% or massive LV dilatation (LVESD >70 mm)—these patients have poor outcomes and should be evaluated for advanced heart failure therapies instead 5

  3. Do not assume all severe MR requires intervention—in secondary MR, the valve is not the primary problem; treating the underlying cardiomyopathy is paramount 1, 6

  4. Ensure procedures are performed at experienced heart valve centers with multidisciplinary heart teams—outcomes are highly dependent on operator and center experience 1, 5

  5. For primary MR, do not delay surgery until symptoms develop if LV dysfunction (LVEF ≤60% or LVESD ≥40 mm) is already present—irreversible myocardial damage may occur 2

Role of the Heart Team

All treatment decisions should involve a multidisciplinary heart valve team including cardiac surgeons, interventional cardiologists, heart failure specialists, imaging specialists, and cardiac anesthesiologists 1, 3, 5. This is particularly critical for secondary MR where the evidence for intervention is less robust and patient selection is paramount.

References

4
Research

When to prefer MitraClip over cardiac surgery.

European heart journal supplements : journal of the European Society of Cardiology, 2026

Related Questions

Is it safe to perform laparoscopic cholecystectomy in a patient with severe mitral regurgitation, and what pre‑operative cardiac assessment and intra‑operative precautions are required?
Can severe mitral regurgitation cause dizziness?
In a 29-year-old asymptomatic man with a systolic murmur at the apex that increases with sustained handgrip and decreases with the Valsalva maneuver, what is the most likely cause?
How should moderate-to-severe mitral regurgitation be managed?
What blood pressure targets and antihypertensive management are recommended for patients with mitral valve regurgitation?
What are the non‑organic causes of excessive afternoon sleepiness and how can it be managed with evidence‑based lifestyle interventions and reliable resources?
What are the possible etiologies of a swollen eyelid in a patient with sickle cell disease?
Is piperacillin‑tazobactam (Zosyn) safe for use during pregnancy?
What is the most likely primary cause of hyponatremia in a 75-year-old woman presenting with intermittent weakness and light‑headedness?
What is the appropriate management of ethmoid sinusitis in a patient with sickle cell disease?
In a patient with non‑small cell lung cancer (NSCLC) without actionable driver alterations (EGFR, ALK, ROS1, BRAF V600E, MET exon‑14, RET, NTRK, KRAS G12C), what is the recommended first‑line immunotherapy approach based on programmed death‑ligand 1 (PD‑L1) expression and overall health status?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.